Media coverage about Ligand Pharmaceuticals (NASDAQ:LGND) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ligand Pharmaceuticals earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.1221255122822 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news headlines that may have effected Accern’s scoring:
- Aradigm Files MAA for Bronchiectasis Candidate in the EU (finance.yahoo.com)
- Ligand Pharmaceuticals Inc. (LGND) Expected to Post Quarterly Sales of $25.99 Million (americanbankingnews.com)
- Ligand Pharmaceuticals (LGND) Upgraded at BidaskClub (americanbankingnews.com)
- Ligand Pharmaceuticals Inc. (LGND) Director Sells $1,317,975.00 in Stock (americanbankingnews.com)
- Corcept Plans Korlym Label Expansion, Pipeline in Progress (finance.yahoo.com)
LGND has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $169.00 target price on shares of Ligand Pharmaceuticals in a research note on Thursday, January 18th. Craig Hallum reiterated a “buy” rating and issued a $170.00 target price (up previously from $160.00) on shares of Ligand Pharmaceuticals in a research note on Wednesday, November 15th. Finally, Roth Capital set a $158.00 target price on Ligand Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, November 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $161.00.
Ligand Pharmaceuticals (NASDAQ:LGND) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.12. Ligand Pharmaceuticals had a return on equity of 14.44% and a net margin of 8.90%. The firm had revenue of $50.50 million during the quarter, compared to analyst estimates of $49.39 million. During the same quarter last year, the firm earned $1.25 EPS. Ligand Pharmaceuticals’s quarterly revenue was up 32.2% on a year-over-year basis. equities research analysts forecast that Ligand Pharmaceuticals will post 3.59 earnings per share for the current year.
In other Ligand Pharmaceuticals news, Director John W. Kozarich sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $145.00, for a total transaction of $362,500.00. Following the completion of the sale, the director now owns 33,149 shares in the company, valued at approximately $4,806,605. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Stephen L. Sabba sold 925 shares of the firm’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $137.25, for a total value of $126,956.25. Following the sale, the director now owns 26,985 shares of the company’s stock, valued at approximately $3,703,691.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 99,890 shares of company stock valued at $15,767,270. 8.30% of the stock is owned by insiders.
WARNING: This piece of content was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3258524/ligand-pharmaceuticals-lgnd-receives-media-sentiment-score-of-0-22.html.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.